Skip to main content


Figure 7 | Diabetology & Metabolic Syndrome

Figure 7

From: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats

Figure 7

Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at Ser256 (Panel A), glucose-6-phosphatase (Panel B), and PEPCK (Panel C). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel.

Back to article page